- Home
- BHVN
BHVN
Biohaven Ltd.
as of 12-08-2025 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.1B | IPO Year: | 2017 |
| Target Price: | $29.79 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.48 - $45.87 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 2219.74% |
AI-Powered BHVN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
VP, Chief Accounting Officer
Avg Cost/Share
$8.52
Shares
17,000
Total Value
$144,770.30
Owned After
20,000
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$7.50
Shares
666,666
Total Value
$4,999,995.00
Owned After
1,195,275
Director
Avg Cost/Share
$7.50
Shares
3,333,333
Total Value
$24,999,997.50
Owned After
5,653,904
SEC Form 4
Director
Avg Cost/Share
$7.50
Shares
400,000
Total Value
$3,000,000.00
Owned After
2,020,071
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Clark George C. | BHVN | VP, Chief Accounting Officer | Nov 17, 2025 | Buy | $8.52 | 17,000 | $144,770.30 | 20,000 | |
| Coric Vlad | BHVN | Chief Executive Officer | Nov 13, 2025 | Buy | $7.50 | 666,666 | $4,999,995.00 | 1,195,275 | |
| CHILDS JOHN W | BHVN | Director | Nov 13, 2025 | Buy | $7.50 | 3,333,333 | $24,999,997.50 | 5,653,904 | |
| Bailey Gregory | BHVN | Director | Nov 13, 2025 | Buy | $7.50 | 400,000 | $3,000,000.00 | 2,020,071 |
Compare BHVN vs Leading Stocks
See how BHVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.